Get the Stockscreener App
0.9265
3.02%
0.0272
Invivyd Inc stock is traded at $0.9265, with a volume of 201.04K.
It is up +3.02% in the last 24 hours and down -2.52% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$0.8993
Open:
$0.92
24h Volume:
201.04K
Relative Volume:
0.45
Market Cap:
$109.67M
Revenue:
-
Net Income/Loss:
$-198.64M
P/E Ratio:
-0.5755
EPS:
-1.61
Net Cash Flow:
$-173.78M
1W Performance:
+2.16%
1M Performance:
-2.52%
6M Performance:
-61.71%
1Y Performance:
-39.05%
1-Day Range:
$0.90
$0.9387
1-Week Range:
$0.89
$0.9648
52-Week Range:
$0.8116
$5.195
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
EF Hutton Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - MSN
Invivyd (NASDAQ:IVVD) Upgraded at EF Hutton Acquisition Co. I - Defense World
Invivyd (NASDAQ:IVVD) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy" Rating - MarketBeat
Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M - MSN
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability - The Manila Times
Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 - Marketscreener.com
Head to Head Review: Prime Medicine (NYSE:PRME) and Invivyd (NASDAQ:IVVD) - Defense World
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update - MarketBeat
Guggenheim upgrades Invivyd Inc (IVVD) stock to a Buy - Knox Daily
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 - The Manila Times
Point72 Asia Singapore Pte. Ltd. Sells 40,079 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data - The Manila Times
Invivyd Inc: Rising -81.14% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Invivyd Inc [IVVD] Records 200-Day SMA of $2.5044 - Knox Daily
Duquesne Family Office LLC Takes $629,000 Position in Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Take off with Invivyd Inc (IVVD): Get ready for trading - SETE News
Invivyd reports stable pemivibart potency against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports stable pemivibart potency against SARS-CoV-2 - Investing.com
Invivyd Inc (IVVD) is a good investment, but the stock may be undervalued - US Post News
Investor’s Toolkit: Key Ratios for Assessing Invivyd Inc (IVVD)’s Performance - The Dwinnex
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) - ForexTV.com
Invivyd (IVVD) Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA - StreetInsider.com
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated - Daily Guardian Canada
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Global BMI Index - Marketscreener.com
Acadian Asset Management LLC Acquires 474,301 Shares of Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Biotech Co. Escapes Stock-Drop Suit Over COVID-19 Drug - Law360
Invivyd Inc (IVVD)’s highs and lows: A closer look at its stock price fluctuations - US Post News
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate - Yahoo Finance
IVVD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
A company insider recently sold 112,381 shares of Invivyd Inc [IVVD]. Should You Sale? - Knox Daily
When Will Invivyd, Inc. (NASDAQ:IVVD) Breakeven? - Simply Wall St
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 - ForexTV.com
Enphase, First Solar, FedEx, Progyny, Steelcase, and More Stock Market Movers - Barron's
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates - MSN
Adagio Therapeutics Stock Hits 52-Week Low at $0.84 Amid Challenges - Investing.com
Invivyd Inc [IVVD] stock for 186,575 USD was sold by MCGUIRE TERRANCE - Knox Daily
Invivyd to Participate in Upcoming Investor Conferences - Yahoo Finance UK
Invivyd begins Phase 1 trial for new COVID-19 antibody - Investing.com India
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ - ForexTV.com
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation ... - Post Register
Invivyd (NASDAQ:IVVD) Receives Buy Rating from HC Wainwright - Defense World
Invivyd shares hold Buy as new data and updates bolster COVID-19 strategy - Investing.com
Ratio Examination: Invivyd Inc (IVVD)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest - ForexTV.com
Analytical Overview: Invivyd Inc (IVVD)’s Ratios Tell a Financial Story - The Dwinnex
Invivyd shares hold Buy rating with price target post-data By Investing.com - Investing.com Australia
Invivyd shares hold Buy rating with price target post-data - Investing.com India
Recent Insider Activity Could Benefit Invivyd Inc (IVVD) - Knox Daily
Views of Wall Street’s Leading Experts on Invivyd Inc - SETE News
Invivyd’s (IVVD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adimab, LLC | 10% Owner |
Jan 19 '24 |
Sale |
3.95 |
5,000,000 |
19,750,000 |
21,687,906 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):